Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02026349 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults - T705US316
A Phase 3 study, sponsored by MDVI.
- Completed
- Registry status
- Phase 3
- Development phase
- 860
- Enrollment target
NCT02026349: Completed Phase 3 study, sponsored by MDVI.
NCT02026349 is a Phase 3 study that has completed, run by MDVI. The registered enrollment target is 860 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (11% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02026349, a Phase 3 study, has completed, sponsored by MDVI.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 860 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if favipiravir is effective in reducing the time to resolution of influenza symptoms.
Primary Outcome
Time from the start of study treatment until alleviation of all primary influenza symptoms (i.e. cough, sore throat, headache, nasal congestion, body aches and pains, fatigue) and to resolution of fever. Subjects will be considered to have symptoms alleviated if individual symptoms are no greater than mild and are confirmed to be no greater than mild at least 21.5 hours later. Similarly, resolution of fever is defined as temperature (oral) measurements to be \< 38.0°C (\<100.4°F) for subjects \<
Interventions
- DRUG Placebo
- DRUG favipiravir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 860 participants |
| Start Date | 2014-01 |
| Est. Completion | 2015-03 |
| Phase | Phase 3 |
What the finished NCT02026349 record still lists
NCT02026349 is an interventional study that assigns participants to a tested intervention. The registered 860 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (11% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02026349 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02026349 about?
NCT02026349 is a clinical study titled "Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults - T705US316". The purpose of this study is to determine if favipiravir is effective in reducing the time to resolution of influenza symptoms.
What is the current status of trial NCT02026349?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 860 participants. The study started on 2014-01. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02026349?
The interventions under investigation include: Placebo (DRUG), favipiravir (DRUG).
Who is sponsoring clinical trial NCT02026349?
This trial is sponsored by MDVI, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02026349's enrollment target sits among peer trials
860 380th of 2000 higher than 1,618 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04541381 · 860 participants · NA
The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
- NCT05211895 · 860 participants · Phase 3
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
- NCT06161025 · 860 participants · Phase 2
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- NCT06541574 · 860 participants · Phase 2
Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia